R-(-)-methamphetamine

Phase 1Small molecule

UUniversity of Wisconsin, Madison

R-(-)-methamphetamine is one of 4 small molecule programs targeting Methamphetamine. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MethamphetamineNot yet recruiting

MethamphetaminePhase 1

Not yet recruiting

Competition

Competitive Landscape

4 competitors in Methamphetamine

#DrugCompanyPhaseTrials

Desoxyn

AAjenat

Approved

6 2

Ozempic

Novo Nordisk

Phase 2

1 3

Psilocybin

COMPASS Pathways

Phase 1

1 4

R-(-)-methamphetamine

UUniversity of Wisconsin, Madison

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Not yet recruiting

Methamphetamine

NCT06746831

Clinical

Trials by Indication[1]

Methamphetamine1 trial

The Low-Down on Methamphetamine Isomers: Prevalence and Pharmacology in Humans

Not yet recruiting·UUniversity of Wisconsin, Madison·Phase 1·NCT06746831·17 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for R-(-)-methamphetamine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — R-(-)-methamphetamine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for R-(-)-methamphetamine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Wisconsin, Madison company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUniversity of Wisconsin, Madison

R-(-)-methamphetamine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Methamphetamine1 trial

References

Drug Info

Quick Facts

Related News